Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer

In the last few years the advent of targeted therapies against oncogenic drivers significantly improved the survival of non small cell lung cancer (NSCLC) patients with a favourable toxicity profile. Therefore, genetic testing, including at least EGFR mutations and ALK/ROS1 rearrangements, should be...

Descripción completa

Detalles Bibliográficos
Autores principales: Tartarone, Alfredo, Lapadula, Vittoria, Di Micco, Concetta, Rossi, Gemma, Ottanelli, Carlotta, Marini, Andrea, Giorgione, Roberta, Ferrari, Katia, Catalano, Martina, Voltolini, Luca, Mini, Enrico, Roviello, Giandomenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176852/
https://www.ncbi.nlm.nih.gov/pubmed/34094913
http://dx.doi.org/10.3389/fonc.2021.632256
Descripción
Sumario:In the last few years the advent of targeted therapies against oncogenic drivers significantly improved the survival of non small cell lung cancer (NSCLC) patients with a favourable toxicity profile. Therefore, genetic testing, including at least EGFR mutations and ALK/ROS1 rearrangements, should be performed in all NSCLC patients (in particular with adenocarcinoma) who received a diagnosis of advanced disease. This review focuses on novel druggable oncogenic drivers, such as MET exon 14 mutations/MET amplification, RET fusions, BRAF V600E mutations, KRAS G12C mutations, NTRK rearrangements, and HER2 alterations.

Ejemplares similares